secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0000950170-23-026748
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met
--------------------------------------------------------------------------------

- Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).
- Pamrevlumab was generally safe and well tolerated; most adverse events were mild or moderate.
- Topline results from LELANTOS-2 Phase 3 study in ambulatory DMD patients expected in Q3 2023.
- CEO Enrique Conterno expressed disappointment and thanked patients, caregivers, and investigators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/0000950170-23-026748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/fgen-20230607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer